MONTEREY, Calif. — For someone who is bothered by their low-lying eyelids, Upneeq may be an option, a speaker here told colleagues at the Women in Ophthalmology Summer Symposium.
Upneeq (oxymetazoline hydrochloride ophthalmic solution 0.1%, RVL Pharmaceuticals) is FDA approved for acquired ptosis, offering a nonsurgical, temporary eyelid lift for patients with mild-moderate acquired ptosis.
“It's interesting because the eyes are the central feature of beauty for the face, yet the eyes and the eyelids have been underserved by nonsurgical treatments,” Andrea L. Kossler, MD,